Medical Device News Magazine reports breaking biotechnology news including new biotech developments, pharmaceuticals and more.
As we delve into the intricate world of biomedical waste, we’ll uncover its significance in preventing disease outbreaks, especially in places like Houston, a city that thrives on medical advancements.
“For this incredibly high-risk patient population, speed and data-rich insights matter,” said Gordon Sanghera, PhD, CEO of Oxford Nanopore Technologies. “We are excited to team up with Fabric Genomics to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data in paediatric care settings that will make it easier for healthcare providers to leverage genetic insights and, in the future, support the health and wellbeing of children and families.”
By introducing lab-grown vessels, Frontier Bio is championing a future where reliance on such animal testing is significantly reduced, if not eliminated.
The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens. HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.
SOPHIA GENETICS notes the three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science.
Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport (NASDAQ: CYRX), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced a new strategic partnership.